Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 15, 2024 22:51 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 4,483 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,483 Underlying: Common Stock · 4,483 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:51 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantStock Option · Derivative | 22,529 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,529 Underlying: Common Stock · 22,529 shares Expires 2034-02-13 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:51 UTC |
ROBERTS EIRYChief Medical Officer
|
SaleCommon Stock | 1,114 | $132.96 | $148,121.78 |
DisclosureSEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,716 F1 · kind: Sale of 1,114 shares of common stock issued upon vesting of 2,113 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (999) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:48 UTC |
Onyia JudeChief Scientific Officer
|
GrantRestricted Stock Unit · Derivative | 10,760 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000075 · wk-form4_1708037291.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,760 Underlying: Common Stock · 10,760 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:48 UTC |
Onyia JudeChief Scientific Officer
|
GrantStock Option · Derivative | 54,069 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000075 · wk-form4_1708037291.xml · derivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,069 Underlying: Common Stock · 54,069 shares Expires 2034-02-13 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:48 UTC |
Onyia JudeChief Scientific Officer
|
SaleCommon Stock | 1,432 | $132.94 | $190,371.08 |
DisclosureSEC source: 0000914475-24-000075 · wk-form4_1708037291.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,128 F1 · kind: Sale of 1,432 shares of common stock issued upon vesting of 2,717 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,285) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $133.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 8,070 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,070 Underlying: Common Stock · 8,070 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
GrantStock Option · Derivative | 40,552 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · derivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,552 Underlying: Common Stock · 40,552 shares Expires 2034-02-13 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,098 | $132.99 | $146,028.40 |
DisclosureSEC source: 0000914475-24-000074 · wk-form4_1708037139.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,740 F1 · kind: Sale of 1,098 shares of common stock issued upon vesting of 2,083 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (985) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:43 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 22,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,415 Underlying: Common Stock · 22,415 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:43 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantStock Option · Derivative | 112,644 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · derivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,644 Underlying: Common Stock · 112,644 shares Expires 2034-02-13 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:43 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 2,832 | $133.02 | $376,700.46 |
DisclosureSEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 514,596 F1 · kind: Sale of 2,832 shares of common stock issued upon vesting of 5,376 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,544) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $134.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:40 UTC |
Gano KyleChief Business Development Off
|
GrantRestricted Stock Unit · Derivative | 8,966 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000072 · wk-form4_1708036809.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,966 Underlying: Common Stock · 8,966 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:40 UTC |
Gano KyleChief Business Development Off
|
GrantStock Option · Derivative | 45,058 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000072 · wk-form4_1708036809.xml · derivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,058 Underlying: Common Stock · 45,058 shares Expires 2034-02-13 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:40 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,352 | $132.89 | $179,673.63 |
DisclosureSEC source: 0000914475-24-000072 · wk-form4_1708036809.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,166 F1 · kind: Sale of 1,352 shares of common stock issued upon vesting of 2,566 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,214) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $133.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:38 UTC |
Delaet IngridChief Regulatory Officer
|
GrantRestricted Stock Unit · Derivative | 5,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,604 Underlying: Common Stock · 5,604 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:38 UTC |
Delaet IngridChief Regulatory Officer
|
GrantStock Option · Derivative | 28,161 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · derivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,161 Underlying: Common Stock · 28,161 shares Expires 2034-02-13 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:38 UTC |
Delaet IngridChief Regulatory Officer
|
SaleCommon Stock | 716 | $133.03 | $95,252.77 |
DisclosureSEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: Sale of 716 shares of common stock issued upon vesting of 1,358 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (642) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.52. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:35 UTC |
Cooke JulieChief Human Resources Officer
|
GrantRestricted Stock Unit · Derivative | 5,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · derivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,604 Underlying: Common Stock · 5,604 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:35 UTC |
Cooke JulieChief Human Resources Officer
|
GrantStock Option · Derivative | 28,161 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · derivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,161 Underlying: Common Stock · 28,161 shares Expires 2034-02-13 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:35 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 796 | $133.04 | $105,902.15 |
DisclosureSEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,976 F1 · kind: Sale of 796 shares of common stock issued upon vesting of 1,509 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (713) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:33 UTC |
Boyer David W.Chief Corp. Affairs Officer
|
GrantRestricted Stock Unit · Derivative | 6,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · derivative · entry 4 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,165 Underlying: Common Stock · 6,165 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:33 UTC |
Boyer David W.Chief Corp. Affairs Officer
|
GrantStock Option · Derivative | 30,977 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · derivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,977 Underlying: Common Stock · 30,977 shares Expires 2034-02-13 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:33 UTC |
Boyer David W.Chief Corp. Affairs Officer
|
SaleCommon Stock | 856 | $133.05 | $113,889.43 |
DisclosureSEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,895 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:33 UTC |
Boyer David W.Chief Corp. Affairs Officer
|
SaleCommon Stock | 955 | $133.10 | $127,106.30 |
DisclosureSEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,751 F1 · kind: Sale of 955 shares of common stock issued upon vesting of 1,811 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (856) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:29 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 7,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000068 · wk-form4_1708036181.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,846 Underlying: Common Stock · 7,846 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:29 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantStock Option · Derivative | 39,426 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000068 · wk-form4_1708036181.xml · derivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,426 Underlying: Common Stock · 39,426 shares Expires 2034-02-13 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:29 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 1,098 | $133.01 | $146,050.36 |
DisclosureSEC source: 0000914475-24-000068 · wk-form4_1708036181.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,616 F1 · kind: Sale of 1,098 shares of common stock issued upon vesting of 2,083 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (985) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:27 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 8,966 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000067 · wk-form4_1708036041.xml · derivative · entry 3 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,966 Underlying: Common Stock · 8,966 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:27 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantStock Option · Derivative | 45,058 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000067 · wk-form4_1708036041.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,058 Underlying: Common Stock · 45,058 shares Expires 2034-02-13 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:27 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 1,352 | $132.85 | $179,611.58 |
DisclosureSEC source: 0000914475-24-000067 · wk-form4_1708036041.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,528 F1 · kind: Sale of 1,352 shares of common stock issued upon vesting of 2,566 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,214) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $133.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:46 UTC |
Boyer David W.Chief Corp. Affairs Officer
|
SaleCommon Stock | 628 | $136.78 | $85,897.84 |
DisclosureSEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 4 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,895 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:46 UTC |
Boyer David W.Chief Corp. Affairs Officer
|
SaleCommon Stock | 700 | $134.19 | $93,932.30 |
DisclosureSEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,523 F3 · kind: Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:35 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 629 | $136.78 | $86,034.62 |
DisclosureSEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,263 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:35 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 700 | $134.23 | $93,960.86 |
DisclosureSEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,892 F4 · kind: Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:28 UTC |
ROBERTS EIRYChief Medical Officer
|
SaleCommon Stock | 980 | $134.21 | $131,521.98 |
DisclosureSEC source: 0000914475-24-000049 · wk-form4_1707438524.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,717 F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5 · balance_after: 18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:25 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 911 | $134.24 | $122,288.90 |
DisclosureSEC source: 0000914475-24-000048 · wk-form4_1707438316.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,755 F3 · kind: Sale of 911 shares of common stock issued upon vesting of 1,727 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (816) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:21 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 2,274 | $134.15 | $305,052.32 |
DisclosureSEC source: 0000914475-24-000046 · wk-form4_1707438093.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 506,962 F3 · kind: Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.75 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:17 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 980 | $134.20 | $131,519.14 |
DisclosureSEC source: 0000914475-24-000045 · wk-form4_1707437835.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,952 F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:15 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 980 | $134.19 | $131,508.65 |
DisclosureSEC source: 0000914475-24-000044 · wk-form4_1707437696.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,631 F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:12 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 980 | $134.21 | $131,529.23 |
DisclosureSEC source: 0000914475-24-000043 · wk-form4_1707437515.xml · nonDerivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,314 F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8 , 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:46 UTC |
Boyer David W.Chief Corp. Affairs Officer
|
SaleCommon Stock | 216 | $141.96 | $30,663.36 |
DisclosureSEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,894 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:46 UTC |
Boyer David W.Chief Corp. Affairs Officer
|
SaleCommon Stock | 240 | $141.96 | $34,070.40 |
DisclosureSEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,110 F1 · kind: Sale of 240 shares of common stock issued upon vesting of 456 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (216) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:35 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 575 | $141.96 | $81,627.00 |
DisclosureSEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,263 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:35 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 640 | $142.17 | $90,989.76 |
DisclosureSEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,838 F1 · kind: Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.05 to $143.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:28 UTC |
ROBERTS EIRYChief Medical Officer
|
SaleCommon Stock | 1,121 | $142.24 | $159,446.11 |
DisclosureSEC source: 0000914475-24-000049 · wk-form4_1707438524.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,837 F1 · kind: Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.40 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:25 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,041 | $142.17 | $147,995.12 |
DisclosureSEC source: 0000914475-24-000048 · wk-form4_1707438316.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,939 F1 · kind: Sale of 1,041 shares of common stock issued upon vesting of 1,975 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (934) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:21 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,040 | $142.18 | $432,218.38 |
DisclosureSEC source: 0000914475-24-000046 · wk-form4_1707438093.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 504,919 F1 · kind: Sale of 3,040 shares of common stock issued upon vesting of 5,771 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,731) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:17 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,600 | $142.20 | $227,522.08 |
DisclosureSEC source: 0000914475-24-000045 · wk-form4_1707437835.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,072 F1 · kind: Sale of 1,600 shares of common stock issued upon vesting of 3,037 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,437) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.07 to $142.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:15 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 1,280 | $142.12 | $181,910.02 |
DisclosureSEC source: 0000914475-24-000044 · wk-form4_1707437696.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,751 F1 · kind: Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $142.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.